ArticleCell death and differentiation2021
Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis.
Open access · hybridAbstract read
In one paragraph
Article in Cell death and differentiation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy.Nature reviews. Clinical oncology · 2023Pooled it
- AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants.European journal of cancer (Oxford, England : 1990) · 2023Guideline
- Microbial product translocation and mortality in adults hospitalised with HIV-associated tuberculosis: a prospective observational cohort study.Research square · 2026Article
- Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans.iScience · 2026Article
- Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study.Bone marrow transplantation · 2026Article
- Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020-2024.Antimicrobial agents and chemotherapy · 2025Article
- Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines.Research square · 2025Article
- Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy.Journal of medical virology · 2025Article
- Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors.Frontiers in immunology · 2025Article
- Brain Pathology in COVID-19: Clinical Manifestations and Potential Mechanisms.Neuroscience bulletin · 2024Review
- Increased Risk of Invasive Aspergillosis in Immunocompromised Patients With Persistent SARS-CoV-2 Viral Shedding >8 Weeks, Retrospective Case-control Study.Open forum infectious diseases · 2024Article
- Clinical characteristics and outcomes among critically ill patients with cancer and COVID-19-related acute respiratory failure.BMC pulmonary medicine · 2024Observational
- Use of remdesivir for COVID-19 in patients with hematologic cancer.Clinical and experimental medicine · 2023Article
- Updated COVID-19 clearance time among patients with cancer in the Delta and Omicron waves.Cancer medicine · 2023Article
- Diagnostic, Prognostic and Mechanistic Biomarkers of COVID-19 Identified by Mass Spectrometric Metabolomics.Metabolites · 2023Review
- Severe acute respiratory syndrome coronavirus-2 Alpha variant (B.1.1.7), original wild-type severe acute respiratory syndrome coronavirus 2, and cytomegalovirus co-infection in a young adult with acute lymphoblastic leukemia, case report, and review of the possible cytomegalovirus reactivation mechanisms.Journal of medical case reports · 2023Article
- Risk Factors Associated with Prolonged Nasopharyngeal Carriage of SARS-CoV-2 and Length of Stay among Patients Admitted to a COVID-19 Referral Center in Manila, Philippines.Acta medica Philippina · 2023Article
- RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies.Oncoimmunology · 2023Article
- SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.The oncologist · 2022Article
- Liver resection in a patient with persistent positive PCR test for coronavirus disease 2019 (COVID-19): a case report.Surgical case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
69 authors at 16 institutions in 9 countries.
Anne-Gaëlle Goubet *Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0003-3431-3067
Agathe Dubuisson *Gustave Roussy Cancer Campus, Villejuif, France.ORCID http://orcid.org/0000-0002-7526-0769
Arthur GeraudGustave Roussy Cancer Campus, Villejuif, France.
François-Xavier DanlosGustave Roussy Cancer Campus, Villejuif, France.
Safae TerrisseGustave Roussy Cancer Campus, Villejuif, France.
Carolina Alves Costa SilvaGustave Roussy Cancer Campus, Villejuif, France.
Damien DrubayGustave Roussy Cancer Campus, Villejuif, France.
Lea TouriGustave Roussy Cancer Campus, Villejuif, France.
Marion PicardGustave Roussy Cancer Campus, Villejuif, France.
Marine MazzengaGustave Roussy Cancer Campus, Villejuif, France.
Aymeric SilvinGustave Roussy Cancer Campus, Villejuif, France.
Garett DunsmoreGustave Roussy Cancer Campus, Villejuif, France.
Yacine HaddadGustave Roussy Cancer Campus, Villejuif, France.
Eugenie PizzatoGustave Roussy Cancer Campus, Villejuif, France.
Pierre LyGustave Roussy Cancer Campus, Villejuif, France.
Caroline FlamentGustave Roussy Cancer Campus, Villejuif, France.
Cléa MelenotteGustave Roussy Cancer Campus, Villejuif, France.
Eric SolaryUniversité Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-8629-1341
Michaela FontenayUniversité de Paris, Institut Cochin, Centre National de la Recherche Scientifique UMR8104, Institut National de la Santé et de la Recherche Médicale, Paris, France.
Gabriel GarciaGustave Roussy Cancer Campus, Villejuif, France.
Corinne BalleyguierGustave Roussy Cancer Campus, Villejuif, France.
Nathalie LassauUniversité Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
Markus MaeurerImmunotherapy/Immunosurgery, Champalimaud foundation, Lisboa, Portugal.
Claudia Grajeda-IglesiasGustave Roussy Cancer Campus, Villejuif, France.
Nitharsshini NirmalathasanGustave Roussy Cancer Campus, Villejuif, France.
Fanny AprahamianGustave Roussy Cancer Campus, Villejuif, France.
Sylvère DurandGustave Roussy Cancer Campus, Villejuif, France.
Oliver KeppCentre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.ORCID http://orcid.org/0000-0002-6081-9558
Gladys FerrereGustave Roussy Cancer Campus, Villejuif, France.
Cassandra ThelemaqueGustave Roussy Cancer Campus, Villejuif, France.
Imran LahmarGustave Roussy Cancer Campus, Villejuif, France.
Jean-Eudes FahrnerGustave Roussy Cancer Campus, Villejuif, France.ORCID http://orcid.org/0000-0001-6581-8418
Lydia MezianiGustave Roussy Cancer Campus, Villejuif, France.
Abdelhakim Ahmed-BelkacemUniv Paris Est Creteil, INSERM U955, IMRB, Creteil, France.ORCID http://orcid.org/0000-0001-6489-5091
Nadia SaïdaniService de maladies infectieuses, Centre Hospitalier de Cornouaille, Quimper, France.
Bernard La ScolaAix-Marseille Université, Institut de Recherche pour le Développement, Assistance Publique - Hôpitaux de Marseille, Microbes Evolution Phylogeny and Infections, Marseille, France.
Didier RaoultAix-Marseille Université, Institut de Recherche pour le Développement, Assistance Publique - Hôpitaux de Marseille, Microbes Evolution Phylogeny and Infections, Marseille, France.
Stéphanie GentileAix Marseille Univ, School of medicine-La Timone Medical Campus, EA 3279: CEReSS-Health Service Research and Quality of life Center, Marseille, France.
Sébastien CortaredonaInstitut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.
Giuseppe IppolitoScientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy.ORCID http://orcid.org/0000-0002-1076-2979
Benjamin LelouvierVaiomer, Labège, France.
Alain RouletVaiomer, Labège, France.
Fabrice AndreUniversité Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
Fabrice BarlesiGustave Roussy Cancer Campus, Villejuif, France.
Jean-Charles SoriaUniversité Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
Caroline PradonGustave Roussy Cancer Campus, Villejuif, France.
Emmanuelle GalloisGustave Roussy Cancer Campus, Villejuif, France.
Fanny PommeretGustave Roussy Cancer Campus, Villejuif, France.
Emeline ColombaGustave Roussy Cancer Campus, Villejuif, France.
Florent GinhouxSingapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID http://orcid.org/0000-0002-2857-7755
Suzanne KazandjianCedar's Cancer Center, McGill University Healthcare Centre, Montreal, QC, Canada.
Arielle ElkriefCedar's Cancer Center, McGill University Healthcare Centre, Montreal, QC, Canada.
Bertrand RoutyCentre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Makoto MiyaraInstitut National de la Santé et de la Recherche Médicale, U1135, Centre d'Immunologie et des Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Guy GorochovInstitut National de la Santé et de la Recherche Médicale, U1135, Centre d'Immunologie et des Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Eric DeutschUniversité Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-8223-3697
Laurence AlbigesUniversité Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
Annabelle StoclinGustave Roussy Cancer Campus, Villejuif, France.
Bertrand GachotGustave Roussy Cancer Campus, Villejuif, France.
Anne FlorinGustave Roussy Cancer Campus, Villejuif, France.
Mansouria MeradGustave Roussy Cancer Campus, Villejuif, France.
Florian ScotteGustave Roussy Cancer Campus, Villejuif, France.
Souad AssaadCentre Léon Bérard, Lyon, France.
Guido KroemerGustave Roussy Cancer Campus, Villejuif, France.ORCID http://orcid.org/0000-0002-9334-4405
Jean-Yves BlayCentre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0001-7190-120X
Aurélien MarabelleGustave Roussy Cancer Campus, Villejuif, France.ORCID http://orcid.org/0000-0002-5816-3019
Frank GriscelliGustave Roussy Cancer Campus, Villejuif, France.
Laurence Zitvogel *Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France. laurence.zitvogel@gustaveroussy.fr.ORCID http://orcid.org/0000-0003-1596-0998
Lisa Derosa *Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France. lisa.derosa@gustaveroussy.fr.
Inserm · FRInstitut Gustave Roussy · FRUniversité Paris-Saclay · FRAix-Marseille Université · FRCentre National de la Recherche Scientifique · FRMcGill University Health Centre · CAUniversité Claude Bernard Lyon 1 · FRAgency for Science, Technology and Research · SGCentre Hospitalier de Cornouaille · FRCentre Hospitalier de l’Université de Montréal · CACeres · USChampalimaud Foundation · PTHôpital Cochin · FRIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITKarolinska University Hospital · SEUniversité Paris Cité · FR
Funding
European Research Council
Abstract
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and noncancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Cancer patients with a prolonged SARS-CoV-2 RNA detection exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of nonconventional monocytes, and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T-helper cells, and non-naive Granzyme B
Indexed as
Virus SheddingAdolescentAdultAgedAged, 80 and overCohort StudiesCOVID-19DNA, BacterialEnterobacteriaceaeFemaleHumansInterferon Type ILymphopeniaMaleMicrococcaceaeMiddle AgedDNA, BacterialInterferon Type IRNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.